BURLINGAME, Calif., Jan. 24 /PRNewswire/ -- BioSeek, Inc., a leader in
applying integrated human biology systems for developing new therapeutics,
announced today that it has entered into a collaboration agreement with
Dainippon Sumitomo Pharma Co. (DSP), a global biopharmaceutical leader
based in Japan. Under the collaboration, BioSeek will apply its BioMAP(R)
Systems to support compound differentiation, lead development, and drug
candidate selection activities for DSP's discovery programs in the fields
of inflammation and metabolic diseases.
"We are excited to be working closely with DSP, a well respected and
innovative global company, and look forward to supporting their discovery
efforts," commented Michael C. Venuti, Ph.D., CEO of BioSeek. "This
collaboration leverages our technology platform's power in addressing key
decision points in the discovery process, making it extremely valuable to
partners such as DSP."
"The BioMAP(R) platform represents a very compelling approach to
applying human systems biology to pharmaceutical research and development,"
stated Dr. Yuichi Yokoyama, Executive Director at DSP. "BioMAP(R) Systems
deliver otherwise difficult-to-obtain human biological information, which
will help us prioritize leads and candidates."
CTC Laboratory Systems Corporation, a subsidiary of Itochu Techno-
Solutions Corporation, assisted with the closing of this agreement.
BioMAP(R) Systems are a series of human primary cell-based assay
systems designed to replicate the intricate cell and pathway interactions
present in human disease biology. Depending on their mechanism of action,
compounds induce specific patterns of changes in these systems (BioMAP
profiles) that can be compared to a large number of reference profiles in
BioSeek's database. BioMAP profiling provides early insight into human
pharmacological properties of compounds including in-depth characterization
of biological drug function, on- and off-target activities, and biomarker
identification.
About BioSeek
BioSeek is improving the success rate of pharmaceutical research and
development by integrating human biology from the early stages of drug
discovery onward. BioSeek is using BioMAP(R) Systems platform for the
internal discovery and development of new drug candidates in the fields of
inflammation, cardiovascular diseases, autoimmune diseases, and related
indications. BioSeek is also leveraging BioMAP(R) Systems technology in
collaborations to enhance the productivity of its pharmaceutical partners'
pipelines. For more information, go to http://www.bioseekinc.com.
About Dainippon Sumitomo Pharma Co.
Dainnipon Sumitomo Pharma Co.'s Corporate Mission is to broadly
contribute to society through value creation based on innovative research
and development activities for the betterment of healthcare and fuller
lives of people worldwide. For more information, go to
http://www.ds-pharma.co.jp/english.
About CTC Laboratory Systems Corporation
CTC Laboratory Systems Corporation (Tokyo, Japan), a subsidiary of
Itochu Techno-Solutions Corporation, is Japan's leading provider of total
solutions from target ID/VD to clinical trials for pharmaceuticals, and a
variety of solutions for the chemical and food processing industries, as
well as for life sciences research institutions. Additional information on
CTCLS can be found at http://www.ctcls.co.jp.
BioSeek Contacts:
BioSeek, Inc.
Michael Venuti, Ph.D.
CEO
Tel: 650.552.0754
MacDougall Biomedical Communications
Jennifer Greenleaf
Tel: 781.235.3060
SOURCE BioSeek, Inc.
 back to top
Related links:
http://www.bioseekinc.com
http://www.ds-pharma.co.jp/english http://www.ctcls.co.jp
CONTACT:
Michael Venuti, Ph.D., CEO, of BioSeek, Inc.,
+1-650-552-0754; or Jennifer Greenleaf of MacDougall Biomedical
Communications for BioSeek, Inc., +1-781-235-3060
|
